![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
基于达拉图穆马布的治疗方案在复发性/耐药性急性白血病的临床疗效:单中心经验
Yi Dai1, Lin Luo1, Zhenbin Wei1
1Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Annals of hematology
|July 24, 2024
概括
基于达拉图穆马布的救援方案对复发性/耐药性急性白血病 (R/R-AL) 显示出希望. 这种方法实现了70%的响应率,提供了缓解和桥梁到干细胞移植的机会.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 复发性/耐药性急性白血病 (R/R-AL) 存在严重的治疗挑战,预后不佳.
- 在急性髓性白血病 (AML) 和急性淋巴细胞白血病 (ALL) 中都存在CD38表达.
- 达拉图马布是一种抗CD38单克隆抗体,已在多发性骨髓瘤中表现出有效性,并正在研究R/R-AL.
研究的目的:
- 评估基于达拉图穆马布的救援疗法的安全性和有效性,用于R/R-AL的成年患者.
- 评估治疗响应率,生存结果和不良事件.
- 探索这种治疗方案在将患者连接到异性干细胞移植 (ASCT) 的潜力.
主要方法:
- 从2018年7月至2023年5月期间接受R/R-AL治疗的10名成年患者的临床数据的回顾性分析.
- 患者接受了基于达拉图马布的救援疗法.
- 结果包括响应率 (CR,PR),生存数据和不良事件监测.
主要成果:
- 观察到70%的整体响应率 (60%的完整响应,10%的部分响应).
- 在7名响应者中,有3人进行了全基干细胞移植 (ASCT).
- 在先前用venetoclax治疗的R/RAML患者中,再用venetoclax加daratumumab进行治疗,在5名患者中,有3名患者产生反应.
结论:
- 基于达拉图穆马布的救援方案为R/R-AL患者提供了可行的治疗选择,实现了显著的缓解率.
- 该疗法显示了可接受的耐受性,并为ASCT提供了潜在的桥梁.
- 对于R/R-AL治疗,需要进一步研究组合疗法,包括venetoclax.
关键词:
CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38 CD38基于达拉图穆马布的救援方案复发/耐药性急性白血病的复发/耐药性急性白血病.威尼托克拉克斯 (Venetoclax) 是一个属于威尼托克拉克斯的地区.更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
63
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...